Matches in Nanopublications for { ?s ?p "[The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP765324.RAvkfKx6r0h496uME34MxiY2NZJaj4MgkAgQiyn2ieJ_8130_assertion description "[The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP765324.RAvkfKx6r0h496uME34MxiY2NZJaj4MgkAgQiyn2ieJ_8130_provenance.
- assertion description "[The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP765033.RAcRL4YsKkIdkkXLZfdTSbNCAVdHXZ_kzIdF1VcsM6wYg130_assertion description "[The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP765033.RAcRL4YsKkIdkkXLZfdTSbNCAVdHXZ_kzIdF1VcsM6wYg130_provenance.
- assertion description "[The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP499035.RAS7yZPyKhEK7wJFH0l3nVEtnn6tQ4RCXJZJ9Y0cOqOII130_assertion description "[The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499035.RAS7yZPyKhEK7wJFH0l3nVEtnn6tQ4RCXJZJ9Y0cOqOII130_provenance.
- NP247339.RA4nch-2RK_mG1gfPvYLWLfp0TcdPCkx8-N0QpJqBZVGw130_assertion description "[The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP247339.RA4nch-2RK_mG1gfPvYLWLfp0TcdPCkx8-N0QpJqBZVGw130_provenance.
- NP572442.RA5yHw7EevV-BGMPxekRjckhDMW0tc-N_-CSnHzInpb00130_assertion description "[The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP572442.RA5yHw7EevV-BGMPxekRjckhDMW0tc-N_-CSnHzInpb00130_provenance.
- NP499033.RAI1buKggcRwBhG2NEezDArfdDrAcmULfoje83abgjLuQ130_assertion description "[The homozygous co-deletion of MTAP, encoding the enzyme methylthioadenosine phosphorylase, in approximately 90% of mesotheliomas with P16/CDKN2A loss has potential therapeutic applications because MTAP-deficient tumors may be responsive to inhibitors of de novo AMP synthesis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499033.RAI1buKggcRwBhG2NEezDArfdDrAcmULfoje83abgjLuQ130_provenance.